Effect of resveratrol against cisplatin-induced clastogenicity

Günsel BİNGÖL, Mehmet Doğan GÜLKAÇ, Meltem Özlen DİLLİOĞLUGİL, Aylin Özön KANLI


Cisplatin (cDDP) is a widely used chemotherapeutic agent for treating a variety of cancers. The drug can also induce chromosomal aberrations (clastogenicity) in healthy cells in cancer patients. Resveratrol (RES) is a natural polyphenol and has been claimed that it has a high protection against clastogenicity. In this study, we aimed to investigate the effect of resveratrol on cDDP-induced chromosome aberrations in bone marrow cells of Wistar albino male rats. Six groups with six animals in each were orginized. Two different resveratrol doses (12.5 ve 25 mg/kg bw) were used and injected intraperitoneally (ip). Resveratrol doses were applied 5 times during the 24 h study period to coincide with the schedule for the cDDP-RES combination groups. With regard to the experimental schedule, cDDP-RES groups received cDDP (5 mg/kg bw) and RES at either 12.5 or 25 mg/kg bw, 30 min before, concurrently, and then at every 6 h after cDDP administration. RES caused a significant reduction in the frequency of chromosome aberrations compared to those induced with cDDP alone. As a result, repeatedly applied RES doses (12.5 or 25 mg/kg bw) during 24h caused statistically significant reduction at the frequency of cisplatin induced chromosome aberrations. In conclusion, it is evaluated that resveratrol can be an option as an adjuvant treatment.


Cisplatin, Chromosome Aberration, Resveratrol, Anticlastogenic

Full Text:



Adler I.D., El-Tarras A. 1989. Clastogenic effects of cis-diamminedichloroplatinum: I. Induction of chromosomal aberrations in somatic and germinal cells of mice. Mutat. Res. 211: 131–137.

Almeida L., Silva M.V., Falcao A., Soares E., Costa R., Loureiro A.I., Lopes C.F., Rocha J.F., Nunes T., Wright L., Silva P.S. 2009. Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers. Mol. Nutr. Food Res. 53: 7–15.

Amaral C.L.D., Francescato H.D.C., Coimbra T.M., Costa R.S., Darin J.D.C., Antunes L.M.G., Bianchi M.L.P. 2008. Resveratrol attenuates cisplatin-induced nephrotoxicity in rats. Arch. Toxicol. 82: 363–370

Ames B.N. 1989. Endogenous oxidative DNA damage, aging and cancer. Free Rad. Res. Commun. 7: 121–128.

Antunes L.M.G., Takahashi C.S. 1998. Effects of high doses of vitamins C and E against doxorubicin-induced chromosomal damage in Wistar rat bone marrow cells. Mutat. Res. 419: 137–143

Antunes L.M.G., Arauj M.C.P., Darin J.D.C., Bianchi M.L.P. 2000. Effects of the antioxidants curcumin and vitamin C on cisplatin-induced clastogenesis in Wistar rat bone marrow cells. Mutat. Res. 465: 131-137.

Attia S.M. 2012. Influence of resveratrol on oxidative damage in genomic DNA and apoptosis induced by cisplatin. Mutation Res. 741: 22-31

Bingöl G., Gülkaç M.D., Dillioğlugil M.Ö., Polat F., Kanli A.Ö. 2014. Effect of resveratrol on chromosomal aberrations induced by doxorubicin in rat bone marrow cells. Mutation Research/Genetic Toxicology and Environmental Mutagenesis, 766, 1-4

Blasko M., Kvietikova I., Pleskova I., Chalupa I., Kuliffay P., Siracky J. 1987. Cytogenetic changes of human peripheral blood lymhocytes in vitro after exposure to cis-DDP (cis-diamminedichloroplatinum II) and oxo-Pt (cis-diamminedichloro-trans-dihydroxyplatinum IV). Neoplasma, 34: 235-238

Carsten R.E., Bachand A.M., Bailey S.M., Ullrich R.L. 2008. Resveratrol reduces radiation-induced chromosome aberration frequencies in mouse bone marrow cells. Radiat. Res. 169: 633–638

Chamber B.A., Ryan D.P., Paz-Anes L., Garcia-Carbonero R., Calabresi P. 2001. Antineoplastic agents. In: Goodman and Gilman’s The Pharmacological Basis of Therapeutics. 10. ed.: JG. Harman, LE. Limbird, AG. Gilman. The McGraw-Hill Companies. New York, 1425-1431.

Crowell J.A., Korytko P.J., Morrissey R.L., Booth T.D., Levine B.S. 2004. Resveratrol-associated renal toxicity. Toxicol. Sci. 82: 614–619.

Deavall D.G., Martin E.A., Horner J.M., Roberts R. 2012. Drug-Induced Oxidative Stress and Toxicity. Journal of Toxicology. 2012, Article ID 645460, 13 pages.

Edelweiss M.I., Trachtenberg A., Pinheiro E.X., da-Silva J., Riegel M., Lizardo-Daudt H.M., Mattevi M.S. 1995. Clastogenic effect of cisplatin on Wistar rat bone marrow cells. Braz. J. Med. Biol. Res. 28: 679–683.

Edwards J.A., Beck M., Riegger C., Bausch J. 2011. Safety of resveratrol with examples for high purity, trans-resveratrol, resVida. Ann. N.Y.Acad. Sci. 1215: 131-137

Ford C.E., Hamerton J.L. 1956. A colchicine, hypotonic citrate, squash sequence for mammalian chromosomes. Stain Technol. 3: 247–51.

Kliesh U., Adler I.D. 1987. Micronucleus test in bone marrow of mice treated with 1-nitropropane, 2-nitropropane and cis- platin. Mutat. Res. 192: 181–184.

Kode A., Rajendrasozhan S., Caito S., Yang S.R., Megson I.L., Rahman I. 2008. Resveratrol induces glutathione synthesis by activation of Nrf2 and protects against cigarette smoke-mediated oxidative stress in human lung epithelial cells. Am. J. Physiol. 294: L478–L488

Langcake P., Pryce R.J. 1976. The production of Resveratrol by Vitis vinifera and other membres of the Vitaceae as a response to infection or injury. Physiol. Plant Pathol. 9: 77-86

Leonard S.S., Xia C., Jiang B.H., Stinefelt B., Klandorf H., Haris G.K., Shi X. 2003. Resveratrol scavenges reactive oxygen species and effects radicalinduced cellular responses. Biochem Biophys Res Commun. 309: 1017– 1026.

Lu J., Ho C.T., Ghai G., Chen K.Y. 2001. Resveratrol analog, 3, 4, 5, 4′-tetrahydroxystilbene, differentially induces pro-apoptotic p53/Bax gene expression and inhibits the growth of transformed cells but not their normal counterparts. Carcinogenesis, 22(2), 321-328.

Matsuoka A., Furuta A., Masayasu O., Fukuhara K., Miyata N. 2001. Resveratrol, a naturally occurring polyphenol, induces sister chromatid exchanges in a Chinese hamster lung (CHL) cell line. Mutat. Res. 494 (1-2): 107-113.

Ndagi U., Mhlongo N., Soliman M.E. 2017. Metal complexes in cancer therapy – an update from drug design perspective. Drug Design, Development and Therapy, 11, 599–616.

Nunes T., Almeida L., Rocha J.F., Falcao A., Fernandes-Lopes C., Loureiro A.I., Wright L., Silva M.V., Silva P.S. 2009. Pharmacokinetics of trans-resveratrol following repeated administration in healthy elderly and young subjects. J. Clin. Pharmacol. 49 (12): 1477–1482.

Barabas K., Milner R., Lurie D., Adin C. 2008. Cisplatin: a review of toxicities and therapeutic applications. Veterinary and Comparative Oncology, 6: 1–18

Rosselli F., Zaccaro L., Venturi M., Rossi, A.M. 1990. Persistence of drug-induced chromosome aberrations in peripheral blood lymphocytes of the rat. Mutat. Res. 232: 107-114.

Rubilio J.A., Mithieux G., Vega F.V. 2008. Resveratrol protects primary rat hepatocytes against oxidative stres damage: Activation of the Nrf2 transcription factor and augmented activities of antioxidant enzymes. European Journal of Pharmacology 591: 66-72

Sanderson B.J., Ferguson L.R., Denny W.A. 1996. Mutagenic and carcinogenic properties of platinum-based anticancer drugs. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, 355(1) 59-70.

Savage J.R.K. 1976. Classification and relationships of induced chromosomal structural Changes. J. Med. Genet. 13:103–122.

Sengottuvelan M., Deeptha K., Nalini N. 2009. Resveratrol ameliorates DNA damage, prooxidant and antioxidant imbalance in 1,2-dimethylhydrazine induced rat colon carcinogenesis. Chem. Biol. Interact. 181: 193–201.

Schmitt E., Lehmann L., Metzler M., Stoper H. 2002. Hormonal and genotoxic activity of resveratrol Toxicology Letters, 136: 133-142

Sgambato A., Ardito R., Faraglia B., Boninsegna A., Wolf F.I., Cittadini A. 2001. Resveratrol, a natural phenolic compound, inhibits cell proliferation and prevents oxidative DNA damage. Mutation Research, 496: 171–180

Tang J.J., Fan G.J., Dai F., Ding D.J., Wang Q., Lu D.L., Li R.R., Li X.Z., Hu L.M., Jin X.L., Zhou B. 2011. Finding more active antioxidants and cancer chemoprevention agents by elongating the conjugated links of resveratrol. Free Radical Biology and Medicine, 50 (10): 1447-1457

Walle T., Hsieh F., DeLegge M.H., Oatis Jr., J.E. Walle U.K. 2004. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab. Dispos. 32:1377–1382.

Weijl N.I., Cleton F.J., Osanto S. 1997. Free radicals and antioxidants in chemotherapy-induced toxicity, Cancer Treat. Rev., 23: 209–240.

Williams L.D., Burdock G.A., Edwards J.A., Beck M., Bausch J. 2009. Safety studies conducted on high purity trans-resveratrol in experimental animals. Food Chem. Toxicol. 47 (9): 2170-2182

Vitrac X., Desmouliere A., Brouillaud B., Krisa S., Deffieux G., Barthe N., Rosenbaum J., Merillon J.M. 2003. Disrubition of 14C trans-resveratrol, a cancer chemopreventive polyphenol, in mouse tissues after oral administration. Life Sci. 72 (20): 2219-2233

Vogel R., Laschinski G., Speilman H., Ehrlich W., Drevenstedt B., Klosa J., Kröger H. 1991. In vitro studies on genotoxicity and cytotoxicity of the anticancer drugs cisplatin and cofplaton, a caffeine-8-ether plus cisplatinum compound. Mutation Research. 264: 225-230

Wang M., Li J., Rangarajan M., Shao Y., LaVoie E.J., Huang T.C., Ho C.T. 1998. Antioxidative Phenolic Compounds from Sage (Salvia officinalis). Journal of Agricultural and Food Chemistry. 46 (12), 4869-4873

Wenzel E. and Somoza V. 2005. Metabolism and bioavailability of trans-resveratrol. Mol. Nutr. Food Res., 49: 472–481.


  • There are currently no refbacks.